Table 5.
Univariate Model of Factors Associated with Hot Flashes.
| Characteristic | Odds Ratio (95% CI) | P-value |
|---|---|---|
| Age at Diagnosis, per 10 years | 0.98 (0.96,1.00) | 0.027 |
| Body Mass Index, kg/m2 | 1.00 (1.00,1.00) | 0.672 |
| Site of Origin – ovarian vs. uterine | 1.02 (0.97,1.08) | 0.390 |
| Histology – carcinoma vs. other | 1.00 (0.94,1.06) | 0.966 |
| Stage | 0.115 | |
| II vs. I | 1.00 (0.92,1.08) | 0.917 |
| III vs. I | 1.07(1.01,1.13) | 0.025 |
| IV vs. I | 1.02 (0.96,1.08) | 0.501 |
| Prior Radiation Therapy – yes vs. no | 0.98 (0.93,1.03) | 0.397 |
| Number of Prior Lines of Chemotherapy | 1.00 (0.99,1.02) | 0.935 |
| Aromatase Inhibitor | 0.843 | |
| Anastrozole vs. Exemestane | 0.93 (0.73,1.19) | 0.560 |
| Letrozole vs. Exemestane | 0.93 (0.73,1.19) | 0.570 |
| Patient Previously on a SERM – yes vs.no | 0.97 (0.91,1.04) | 0.370 |
| AIMSS-like Symptoms Prior to Start Date – yes vs. no | 0.98 (0.94,1.03) | 0.494 |
| Medications During AI Use | ||
| Duloxetine: yes vs. no | 1.10 (0.87,1.40) | 0.423 |
| Other SNRI (Venlafaxine): yes vs. no | 0.96 (0.90,1.03) | 0.280 |
| SSRI: yes vs. no | 1.01 (0.94,1.08) | 0.831 |
| NSAIDS: yes vs. no | 1.01 (0.96,1.07) | 0.719 |
| Narcotics: yes vs. no | 1.00 (0.94,1.06) | 0.965 |
| Gabapentin: yes vs. no | 1.02 (0.93,1.11) | 0.744 |
| Measurable Disease at AI Initiation – yes vs. no | 0.96 (0.90,1.01) | 0.131 |
Odds ratio is calculated using generalized estimation equation approach to explore associations between hot flashes and factors of interest.
SERM = selective estrogen receptor modulator; AI = aromatase inhibitor; AIMSS = aromatase inhibitor musculoskeletal syndrome; SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin-norepinephrine reuptake inhibitor; NSAID = nonsteroidal anti-inflammatory drug.